Summit Therapeutics Inc. (SMMT): Cash & Equivalents
$225.27M
As of 2025-12-31
$419.37M
As of 2026-06-30
-13.5%
3-year compound annual growth
+27.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $225.27M | +114.8% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $104.86M | +46.8% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $71.42M | -79.5% | 2026-02-23, Balance as of period end |
| 2022-12-31 | $348.61M | +385.6% | 2025-02-24, Balance as of period end |
| 2021-12-31 | $71.79M | +8.1% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $66.42M | +4.0% | 2021-03-31, Balance as of period end |
| 2019-12-31 | $63.84M | n/a | 2021-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $225.27M | +114.8% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $80.16M | -3.9% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $354.73M | +282.9% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
Compare SMMT, AUPH, KNSA, KURA side by side · Screen every company in Pharmaceutical Preparations ↗